RxDoctor Payments DataLook up a doctor →

Alrich Gray, MD

Cardiovascular Disease · Great Falls, MTNPI 1952372294

Payments from drug & device makers

$33,841in general payments, 2019–2025

Across 463 payments — averaging $73.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$12K
  • Medical Device Business Services, Inc.$6K
  • Abbott$5K
  • Boston Scientific$4K
  • Atricure, Inc.$2K
  • Biosense Webster, Inc.$1K
  • plus $4K from 20 others

What the payments were for

  • Travel & lodging$21,28063%
  • Food & beverage$12,41237%
  • Education$1490%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,841 in reported general payments places this provider in the 85th percentile of 49 cardiovascular disease providers in Montana.

See all cardiovascular disease providers in Montana

Medicare billing

Part B allowed, 2024
$571,110
Medicare patients
1,193
Services billed
6,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban513$618,401
EntrestoSacubitril/Valsartan198$295,844
XareltoRivaroxaban193$207,496
FarxigaDapagliflozin Propanediol124$136,406
BrilintaTicagrelor97$77,676
MultaqDronedarone Hcl26$33,701
Repatha SureclickEvolocumab34$25,245
JardianceEmpagliflozin16$23,885
Dofetilide54$11,991
Metoprolol Succinate677$10,565
Praluent PenAlirocumab18$8,481
Repatha SyringeEvolocumab12$7,538
Flecainide Acetate171$5,870
Atorvastatin Calcium371$3,642
Amlodipine Besylate440$2,772

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$310$618,401513 claims
NovartisEntresto$468$295,844198 claims
AstraZenecaFarxiga, Brilinta$435$214,082221 claims
Johnson & JohnsonXarelto$399$207,496193 claims
Sanofi-aventis U.S. LLCMultaq$28$33,70126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 49 cardiovascular disease providers in Montana.

Other cardiovascular disease in Great Falls

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →